within Pharmacolibrary.Drugs.ATC.A;

model A11HA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 2.3333333333333332e-05,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0018333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A11HA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Nicotinamide, also known as niacinamide, is a form of vitamin B3 used as a dietary supplement and medication. It is essential for human health, used to treat and prevent niacin deficiency (pellagra). It is an approved and widely used over-the-counter vitamin supplement.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters as observed in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Irie, J, et al., &amp; Itoh, H (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. <i>Endocrine journal</i> 67(2) 153–160. DOI:<a href=&quot;https://doi.org/10.1507/endocrj.EJ19-0313&quot;>10.1507/endocrj.EJ19-0313</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31685720/&quot;>https://pubmed.ncbi.nlm.nih.gov/31685720</a></p></li><li><p>Trammell, SA, et al., &amp; Brenner, C (2016). Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. <i>Nature communications</i> 7 12948–None. DOI:<a href=&quot;https://doi.org/10.1038/ncomms12948&quot;>10.1038/ncomms12948</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27721479/&quot;>https://pubmed.ncbi.nlm.nih.gov/27721479</a></p></li><li><p>Linnik, IV, et al., &amp; Cheetham, GMT (2019). Pharmacokinetics of the SABRE agent 4,6-d. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 135 32–37. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2019.05.004&quot;>10.1016/j.ejps.2019.05.004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31077749/&quot;>https://pubmed.ncbi.nlm.nih.gov/31077749</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A11HA01;
